Germany – Pharmaceutical products – Open-House-Rabattverträge 2026-16 (aut idem)

The statutory health insurers (whether HEK and/or hkk participate in the respective lot, this results from the designation of the respective lot) aim to conclude discount contracts pursuant to § 130a para. 8 SGB V with all suitable pharmaceutical companies for the active substances, active substance combinations or dosage forms, strengths, or finished medicinal products named in the respective lot title. The contract is concluded within the framework of the open-house procedure: Individual negotiations on contract contents are not conducted, uniform conditions apply. The statutory health insurers do not guarantee exclusivity to individual contracting partners. The contract period is a maximum of 36 months, starting at the earliest on 01.11.2026 (any deviations in start times result from the information for the respective lot). The contract ends at the latest on 31.10.2029 (possible exceptions result from the information for the respective lot), regardless of the date of the contract conclusion. Joining this open-house procedure is possible at any time during the contract period. The medicinal products subject to the procedure are listed in Part B of Annex VII to Section M of the Medicinal Products Directive (list of exclusions from substitution). Therefore, medicinal products covered by the respective lot are, in the specified dosage form, exempt from substitution by an active substance equivalent medicinal product pursuant to § 129 para. 1a sentence 2 SGB V. All further information can be found in the tender and contract documents.